Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 57Melanoma 54Neoplasm Metastasis 49Lung Neoplasms 49Breast Neoplasms 41Neoplasms 36Colorectal Neoplasms 35Head and Neck Neoplasms 25Endometrial Neoplasms 25Carcinoma, Renal Cell 24Uterine Cervical Neoplasms 21Stomach Neoplasms 21Ovarian Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 16Recurrence 15Carcinoma, Hepatocellular 14Pancreatic Neoplasms 13Sarcoma 12Carcinoma, Squamous Cell 12Glioblastoma 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Prostatic Neoplasms 10Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 1Secretin 1Pharmaceutical Preparations 1Nivolumab 1Genome 1Diagnostic Imaging 1Dermoscopy 1CA-19-9 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dysplastic Nevus Syndrome × pembrolizumab × Clear all
NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

University of Pittsburgh

Recruiting
30 enrolled
Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡